EBGLYSS – BiotechReality – Information Intelligence System for Biopharma

Quick Summary Groundbreaking Phase 3 Success for Young Patients: EBGLYSS (lebrikizumab), a selective IL-13 inhibitor, delivered positive Phase 3 results in the ADorable-1 trial for children aged 6 months to 18 years with moderate-to-severe atopic dermatitis, achieving 63% meaningful skin improvement (EASI-75) and 44% clear/almost clear skin versus just 22% and 15% with placebo. Exceptional Safety & Quality of Life Improvements: The medication demonstrated excellent tolerability with no new safety concerns, zero injection site pain reported, and 35% of patients experiencing significant itch relief (≥4-point improvement). Safety profile was consistent with adult studies, making it safe across all pediatric age groups. Eli Lilly declared that EBGLYSS (lebrikizumab-lbkz) has achieved a groundbreaking milestone in dermatology with remarkable Phase 3 results demonstrating its effectiveness in treating pediatric patients with moderate-to-severe atopic dermatitis. The positive outcomes from the ADorable-1 trial represent a significant advancement in the treatment landscape for children aged six months to 18 years suffering from this chronic inflammatory skin condition. Key Phase 3 Results at Week 16 63% of patients achieved meaningful skin improvement (EASI-75) with EBGLYSS. 44% achieved clear or almost clear skin (IGA 0,1) compared to just 15% with placebo. 39% achieved near-complete skin clearance (EASI-90) through IL-13 inhibition. 35% experienced significant itch relief (Pruritus NRS ≥4-point improvement). No injection site pain was reported in any pediatric patients. Understanding EBGLYSS: A Selective IL-13 Inhibitor Breakthrough EBGLYSS represents a paradigm shift in atopic dermatitis treatment through its selective targeting of IL-13 signaling. This monoclonal antibody selectively blocks IL-13, a primary cytokine implicated in the inflammatory cascade that drives atopic dermatitis in both children and adults. By targeting IL-13 with high binding affinity and a slow dissociation rate, EBGLYSS prevents the formation of the IL-13Rα1/IL-4Rα receptor complex, effectively interrupting the type-2 inflammatory cycle in the skin. The mechanism of action is particularly important for pediatric patients because IL-13 is a primary driver of skin barrier dysfunction, itch, skin thickening, and secondary infections in children with moderate-to-severe atopic dermatitis. Unlike broader immunosuppressants, this selective IL-13 inhibitor approach allows for more targeted therapy with potentially fewer systemic effects. The ADorable-1 Trial: Rigorous Pediatric Assessment of EBGLYSS Study Design and Patient Population The Phase 3 ADorable-1 study (NCT05559359) was a randomized, double-blind, placebo-controlled trial that included 363 pediatric patients with moderate-to-severe atopic dermatitis. This landmark study represented the first comprehensive evaluation of an IL-13 inhibitor in children as young as six months, addressing a critical gap in treatment options for the youngest patients. Participants received either a placebo or weight-based dosing of EBGLYSS. The trial protocol required topical corticosteroids beginning two weeks before randomization and throughout the 16-week study period, with the option to discontinue or reduce these medications once patients achieved IGA 2 or less. This design reflects real-world clinical practice while isolating the effects of EBGLYSS. Primary and Secondary Endpoints The study was designed with two co-primary endpoints measuring EBGLYSS effectiveness: EASI-75: A 75% reduction in the Eczema Area and Severity Index from baseline. IGA 0,1: Achievement of clear or almost clear skin (Investigator's Global Assessment 0 or 1). Key secondary endpoints included even greater improvements: EASI-90: A 90% reduction in eczema severity. Pruritus NRS: Four-point or greater improvement in itch severity on the Numeric Rating Scale. Read More: Pfizer Announces Positive Phase 2 Results for Trispecific Antibody Tilrekimig in Moderate to Severe Atopic Dermatitis Impressive Phase 3 Efficacy Data: EBGLYSS Performance vs. Placebo Clinical OutcomeEBGLYSS ResultsPlacebo ResultsDifferenceEASI-75 (Meaningful Improvement)63%22%+41%IGA 0,1 (Clear/Almost Clear)44%15%+29%EASI-90 (Near-Complete Clearance)39%11%+28%Pruritus NRS ≥4-point Improvement35%6%+29% Safety Profile: Why EBGLYSS is Well-Tolerated in Pediatric Patients Consistent Safety Across Age Groups The safety profile of EBGLYSS in pediatric patients demonstrated consistency with that observed in adult and adolescent studies, with no new safety signals identified. This consistency is crucial for pediatric medications, as it suggests the IL-13 inhibitor mechanism is fundamentally safe across different age groups. The most common adverse events occurring in 5% or more of participants were: Upper respiratory tract infections Nasopharyngitis Notably, there was no numerical imbalance between EBGLYSS and placebo groups for these infections, suggesting they were not directly related to the medication. Injection Site Tolerability A significant finding was that injection site reactions were reported similarly between EBGLYSS and placebo treatment arms, with zero cases of injection site pain reported in any pediatric patients. This is particularly important for families administering injections to young children, addressing a common concern with biologic therapies. Read More: Amgen and Kyowa Kirin Announce Positive Top-Line Results from Rocatinlimab Phase 3 Study for Atopic Dermatitis Clinical Significance: Why These EBGLYSS Results Matter Atopic dermatitis affects millions of children, with approximately 9.6 million children in the United States suffering from this condition. One-third of affected children have moderate-to-severe disease requiring systemic treatment. Until now, pediatric patients, especially younger children, have had fewer approved treatment options compared to adults. Children with moderate-to-severe atopic dermatitis often endure relentless skin flares, itch and discomfort that can disrupt play, school and daily life for patients and caregivers. EBGLYSS has already changed what's possible for adults and adolescents, delivering durable results that help patients flare less with the option of monthly maintenance dosing. Now, these data show EBGLYSS also provided disease control in pediatric patients, a critical milestone that, if approved, could bring profound relief to these patients and their families. Adrienne Brown, Executive Vice President and President, Lilly Immunology Impact on Pediatric Dermatology Practice The Phase 3 results establish EBGLYSS as a selective IL-13 inhibitor option that can meaningfully improve outcomes for children with moderate-to-severe atopic dermatitis who have an inadequate response to topical therapies. The achievement of near-complete skin clearance in nearly 40% of pediatric patients represents unprecedented efficacy in this population. Regulatory Path and Future EBGLYSS Development Anticipated Label Expansion Based on the positive Phase 3 results from ADorable-1, Eli Lilly plans to submit these data to U.S. and global regulatory agencies for a potential label expansion of EBGLYSS to include pediatric patients aged six months to 18 years. This regulatory pathway could significantly expand access to this selective IL-13 inhibitor for younger patients. Ongoing Clinical Development The ADorable clinical program extends beyond the Phase 3 trial. ADorable-2, a 52-week extension study of patients enrolled in ADorable-1, is ongoing and will provide critical long-term safety and efficacy data. Additional results from both ADorable trials are expected later in 2026. Read More: AbbVie Reports Breakthrough Results for RINVOQ® (Upadacitinib) in Alopecia Areata Treatment The Broader EBGLYSS Pipeline: Beyond Atopic Dermatitis While the pediatric atopic dermatitis indication represents a major milestone, EBGLYSS development extends across multiple dermatological conditions. The comprehensive Phase 3 program in atopic dermatitis includes seven key global studies evaluating over 1,600 patients: ADvocate 1 and 2: Monotherapy studies. ADhere: Combination therapy with topical corticosteroids. ADjoin: Long-term extension study. ADore: Adolescent open-label study. ADorable 1 and 2: Pediatric studies. Additionally, EBGLYSS is being investigated in other allergic conditions: Allergic rhinitis Chronic rhinosinusitis with nasal polyps Current EBGLYSS Approvals and Availability Global Regulatory Status EBGLYSS has already received approval in multiple key markets: United States (2024) Japan (2024) Canada (2024) European Union (2023) Currently, EBGLYSS is approved as a first-line biologic treatment with a monotherapy option for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis inadequately controlled by topical prescription therapies. Dosing and Administration The current dosing regimen for EBGLYSS includes: Treatment PhaseDosing RegimenFrequencyInitial Phase500 mg (two 250 mg injections)At Week 0 and Week 2Loading Phase250 mg per injectionEvery two weeks until Week 16 or until adequate clinical responseMaintenance Phase250 mg per injectionOnce monthly (every four weeks) Information: Eli Lilly and Company Last Modified:

Tag: EBGLYSS

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment